1️⃣ Protagonist chose certainty over U.S. upside
Protagonist opted out of the 50:50 U.S. profit split with Takeda for rusfertide, taking $200M now and up to another $275M if the FDA approves the PV drug under priority review in Q3.
💡 Why it matters
This is a clean risk-transfer signal. Protagonist keeps royalties and milestones, while Takeda gets full U.S. control before launch. Near-approval assets are being monetized with less romance.
☕ Coffee talk
If the asset is that close to approval, why did Protagonist prefer cash now to owning half the U.S. launch?
2️⃣ Pfizer bought time in ATTR-CM
Pfizer settled Vyndamax patent litigation with Dexcel, Hikma and Cipla, pushing effective U.S. generic tafamidis entry to June 1, 2031, subject to other litigation.
💡 Why it matters
ATTR-CM just got a longer branded runway. That protects Pfizer, but it also reshapes the commercial math for BridgeBio, Alnylam and the next late-stage entrants.
☕ Coffee talk
How many ATTR models still assumed cheap tafamidis would arrive before the market fully matured?
3️⃣ GE HealthCare exposed the imaging margin problem
GE HealthCare grew Q1 revenue 7.4% to $5.1B, but cut 2026 adjusted EPS guidance to $4.80-$5.00 after a PDx supplier issue and higher memory-chip, oil and freight costs.
💡 Why it matters
Demand is not the weak point. Margin is. For medtech and imaging assets, the buyer question shifts from growth to how much supply-chain pain the model can actually absorb.
☕ Coffee talk
If a scaled imaging incumbent is cutting guidance on chips and freight, what happens to smaller hardware stories without that purchasing power?